JP2025501769A5 - - Google Patents

Info

Publication number
JP2025501769A5
JP2025501769A5 JP2024538431A JP2024538431A JP2025501769A5 JP 2025501769 A5 JP2025501769 A5 JP 2025501769A5 JP 2024538431 A JP2024538431 A JP 2024538431A JP 2024538431 A JP2024538431 A JP 2024538431A JP 2025501769 A5 JP2025501769 A5 JP 2025501769A5
Authority
JP
Japan
Prior art keywords
akg
liposome composition
aqueous medium
concentration
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082290 external-priority patent/WO2023122759A2/en
Publication of JP2025501769A publication Critical patent/JP2025501769A/ja
Publication of JP2025501769A5 publication Critical patent/JP2025501769A5/ja
Pending legal-status Critical Current

Links

JP2024538431A 2021-12-22 2022-12-22 オキサゾリジノンリポソーム組成物 Pending JP2025501769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163292899P 2021-12-22 2021-12-22
US63/292,899 2021-12-22
PCT/US2022/082290 WO2023122759A2 (en) 2021-12-22 2022-12-22 Oxazolidinone liposome compositions

Publications (2)

Publication Number Publication Date
JP2025501769A JP2025501769A (ja) 2025-01-23
JP2025501769A5 true JP2025501769A5 (enExample) 2026-01-05

Family

ID=86903807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538431A Pending JP2025501769A (ja) 2021-12-22 2022-12-22 オキサゾリジノンリポソーム組成物

Country Status (12)

Country Link
US (2) US20250064739A1 (enExample)
EP (1) EP4452252A4 (enExample)
JP (1) JP2025501769A (enExample)
KR (1) KR20240152302A (enExample)
CN (1) CN118900689A (enExample)
AR (1) AR128071A1 (enExample)
AU (1) AU2022420614A1 (enExample)
CA (1) CA3241952A1 (enExample)
IL (1) IL313709A (enExample)
MX (1) MX2024007588A (enExample)
WO (1) WO2023122759A2 (enExample)
ZA (1) ZA202404799B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102859152B1 (ko) * 2024-10-24 2025-09-12 주식회사 한국리포좀 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
EP1656370B1 (en) * 2003-06-03 2012-08-15 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
CA3183397A1 (en) * 2020-06-18 2021-12-23 Daryl C. Drummond Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
KR100617921B1 (ko) 리포솜 조성물 및 퀴놀론의 투여 방법
CN110621298B (zh) 阿托品药物组合物
JP2023531666A5 (enExample)
JP2022511732A5 (enExample)
CA2408464A1 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP2025501769A5 (enExample)
US20170231910A1 (en) Pharmaceutical formulations of chelating agents as a metal removal treatment system
IL299155B1 (en) Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
KR20150129727A (ko) 조절 약물 방출 리포솜 조성물
US20170128366A1 (en) Pharmaceutical formulations of chelating agents as a metal removal treatment system
US20080124385A1 (en) Methods for Transmembrane Treatment and Prevention of Otitis Media
WO2023152642A1 (en) Ophthalmic compositions and methods thereof
US20170239182A1 (en) Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
US20200016169A1 (en) Ophthalmic solution of bimatoprost
US20170119666A1 (en) Stable liposomal formulations of alpha 2 adrenergic agonists for ocular delivery
WO2013151518A1 (en) Capsule formulations comprising ceftibuten
JP7149991B2 (ja) 発泡剤を含む抗微生物組成物
AU2024288766A1 (en) Liposome encapsulated apomorphine
KR20240152302A (ko) 옥사졸리디논 리포좀 조성물
CN118161488A (zh) 一种含有jak抑制剂的眼用制剂及其制备方法和应用
JPH029816A (ja) スパガリン類製剤
MXPA00009675A (en) Liposome composition and method for administering a quinolone
CN109982696A (zh) 治疗细菌感染用的脒取代β-内酰胺化合物的脂质体制剂
HK1035331B (en) Liposome composition and method for administering a quinolone